摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(3-(2-(prop-2-ynyloxy)ethoxy)ethoxy)pyridine-2yl]trimethylammonium trifluoromethanesulfonate | 1443654-81-6

中文名称
——
中文别名
——
英文名称
[(3-(2-(prop-2-ynyloxy)ethoxy)ethoxy)pyridine-2yl]trimethylammonium trifluoromethanesulfonate
英文别名
Trifluoromethanesulfonate;trimethyl-[3-[2-(2-prop-2-ynoxyethoxy)ethoxy]pyridin-2-yl]azanium;trifluoromethanesulfonate;trimethyl-[3-[2-(2-prop-2-ynoxyethoxy)ethoxy]pyridin-2-yl]azanium
[(3-(2-(prop-2-ynyloxy)ethoxy)ethoxy)pyridine-2yl]trimethylammonium trifluoromethanesulfonate化学式
CAS
1443654-81-6
化学式
CF3O3S*C15H23N2O3
mdl
——
分子量
428.43
InChiKey
REEMTFVWIBDVAU-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.37
  • 重原子数:
    28
  • 可旋转键数:
    9
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    106
  • 氢给体数:
    0
  • 氢受体数:
    10

反应信息

  • 作为反应物:
    描述:
    [(3-(2-(prop-2-ynyloxy)ethoxy)ethoxy)pyridine-2yl]trimethylammonium trifluoromethanesulfonate 在 [18F]fluoride 、 potassium carbonate 作用下, 以 乙腈 为溶剂, 反应 1.72h, 生成 2-(fluoro-18F)-3-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)pyridine
    参考文献:
    名称:
    2-Fluoropyridine prosthetic compounds for the 18F labeling of bombesin analogues
    摘要:
    Acetylene-bearing 2-[F-18]fluoropyridines [F-18]FPy5yne and PEG-[F-18]FPyKYNE were prepared via efficient nucleophilic heteroaromatic [F-18]fluorination of their corresponding 2-trimethylammoniumpyrdinyl precursors. The prosthetic groups were conjugated to azide- and PEG(3)-modified bombesin(6-14) analogues via copper-catalyzed azide-alkyne cycloaddition couplings to yield mono- and di-mini-PEGylated ligands for PET imaging of the gastrin- releasing peptide receptor. The PEG(3)- and PEG(2)/PEG(3)-bearing F-18 peptides showed decreased lipophilicity relative to an analogous non-mini-PEGylated F-18 peptide. Assessment of water-soluble peptide pharmacokinetics and tumour-targeting capabilities in a mouse model of prostate cancer is currently underway. (c) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.04.060
  • 作为产物:
    参考文献:
    名称:
    2-Fluoropyridine prosthetic compounds for the 18F labeling of bombesin analogues
    摘要:
    Acetylene-bearing 2-[F-18]fluoropyridines [F-18]FPy5yne and PEG-[F-18]FPyKYNE were prepared via efficient nucleophilic heteroaromatic [F-18]fluorination of their corresponding 2-trimethylammoniumpyrdinyl precursors. The prosthetic groups were conjugated to azide- and PEG(3)-modified bombesin(6-14) analogues via copper-catalyzed azide-alkyne cycloaddition couplings to yield mono- and di-mini-PEGylated ligands for PET imaging of the gastrin- releasing peptide receptor. The PEG(3)- and PEG(2)/PEG(3)-bearing F-18 peptides showed decreased lipophilicity relative to an analogous non-mini-PEGylated F-18 peptide. Assessment of water-soluble peptide pharmacokinetics and tumour-targeting capabilities in a mouse model of prostate cancer is currently underway. (c) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.04.060
点击查看最新优质反应信息

文献信息

  • 2-Fluoropyridine prosthetic compounds for the 18F labeling of bombesin analogues
    作者:James Inkster、Kuo-Shyan Lin、Samia Ait-Mohand、Simon Gosselin、François Bénard、Brigitte Guérin、Maral Pourghiasian、Thomas Ruth、Paul Schaffer、Tim Storr
    DOI:10.1016/j.bmcl.2013.04.060
    日期:2013.7
    Acetylene-bearing 2-[F-18]fluoropyridines [F-18]FPy5yne and PEG-[F-18]FPyKYNE were prepared via efficient nucleophilic heteroaromatic [F-18]fluorination of their corresponding 2-trimethylammoniumpyrdinyl precursors. The prosthetic groups were conjugated to azide- and PEG(3)-modified bombesin(6-14) analogues via copper-catalyzed azide-alkyne cycloaddition couplings to yield mono- and di-mini-PEGylated ligands for PET imaging of the gastrin- releasing peptide receptor. The PEG(3)- and PEG(2)/PEG(3)-bearing F-18 peptides showed decreased lipophilicity relative to an analogous non-mini-PEGylated F-18 peptide. Assessment of water-soluble peptide pharmacokinetics and tumour-targeting capabilities in a mouse model of prostate cancer is currently underway. (c) 2013 Elsevier Ltd. All rights reserved.
查看更多